{"product_id":"apyx-vrio-analysis","title":"Apyx Medical Corporation (APYX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Apyx Medical Corporation (APYX) truly built to last? This VRIO analysis cuts straight to the core, dissecting the Value, Rarity, Inimitability, and Organization of its key resources to reveal the definitive source of its competitive advantage - or lack thereof. Dive in now to see the hard truth about Apyx Medical Corporation (APYX)'s sustainability and what it means for its future market position.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eApyx Medical Corporation (APYX) - VRIO Analysis: Proprietary Helium Plasma and Radiofrequency Platform Technology (Renuvion\/J-Plasma)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine of Apyx Medical Corporation's growth story - that proprietary helium plasma and radiofrequency tech, Renuvion\/J-Plasma. Honestly, this platform is what separates them in the surgical aesthetics space right now, and the numbers from 2025 back that up.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Allows for controlled thermal energy delivery to tissue, creating a unique mechanism for aesthetic and surgical applications, driving the core Advanced Energy segment revenue.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis technology is definitely where the money is being made. Look at the third quarter of fiscal year 2025: Surgical Aesthetics revenue hit \u003cstrong\u003e$11.1 million\u003c\/strong\u003e out of total revenue of \u003cstrong\u003e$12.9 million\u003c\/strong\u003e. That means this platform is responsible for about \u003cstrong\u003e86%\u003c\/strong\u003e of the company's top line in that quarter alone. Management is now guiding full-year 2025 revenue between \u003cstrong\u003e$50.5 million\u003c\/strong\u003e and \u003cstrong\u003e$52.5 million\u003c\/strong\u003e, with the Surgical Aesthetics portion expected to be \u003cstrong\u003e$43.0 million\u003c\/strong\u003e to \u003cstrong\u003e$45.0 million\u003c\/strong\u003e. The new AYON system, built on this tech, is the focus, driving that guidance increase. It’s a high-value asset because it delivers a specific, controlled tissue effect that surgeons want.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: The specific combination and application of this platform technology in aesthetic medicine is quite rare among competitors.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhile other companies have energy devices, the specific way Apyx Medical combines helium plasma with radiofrequency for controlled subdermal heating is not something you see replicated easily. What this estimate hides is the competitive landscape, but for now, the market doesn't have a direct, widely adopted substitute. The fact that Renuvion won the 2025 NewBeauty Award for Best Minimally Invasive Skin Tightener shows market recognition of its uniqueness.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: High. The underlying physics is known, but the specific engineering, delivery systems, and clinical data make direct imitation difficult and slow.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt’s not impossible to copy, but it’s certainly not cheap or fast. Anyone trying to replicate this needs to overcome significant engineering hurdles in the delivery system. Plus, Apyx Medical has built a moat with its clinical evidence - they tout support from over \u003cstrong\u003e90 clinical publications\u003c\/strong\u003e. Replicating that body of evidence takes years and millions of dollars in trials. That’s a big barrier to entry, defintely.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: High. The technology is the foundation for both the Renuvion consumables and the new AYON system.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApyx Medical is clearly organized around this platform. They transitioned the AYON commercialization to a full U.S. program in September 2025, showing they are ready to scale sales and support for the integrated system. They also submitted a new 510(k) to the FDA to expand AYON’s label to include power liposuction, showing they are strategically maximizing the platform’s utility across their organization.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on how this all scores out:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eScore (Y\/N)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (Costly to Imitate)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (Exploited)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained. The established clinical backing and integration into the new AYON platform lock in its value.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBecause the technology is valuable, rare, costly to imitate, and Apyx Medical is organized to exploit it - especially with the full AYON launch underway - this translates to a sustained competitive advantage. You want to see them continue to drive adoption of the AYON system, as that locks in the recurring revenue from the Renuvion\/J-Plasma consumables. If onboarding takes 14+ days, churn risk rises, so execution on the sales front is key now.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eApyx Medical Corporation (APYX) - VRIO Analysis: AYON Body Contouring System (FDA-Cleared, Integrated Platform)\n\u003c\/h2\u003e\n\u003cp\u003eThe AYON Body Contouring System, which received \u003cstrong\u003e510(k) FDA clearance\u003c\/strong\u003e in \u003cstrong\u003eMay 2025\u003c\/strong\u003e, is positioned as the first fully integrated platform for the aesthetic surgical suite.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eV\u003c\/strong\u003ealue: The system integrates fat removal, closed loop contouring, tissue contraction (via proprietary Renuvion technology), and electrosurgical capabilities. The commercial launch in \u003cstrong\u003eSeptember 2025\u003c\/strong\u003e immediately contributed to financial performance.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eR\u003c\/strong\u003earity: High. Being the \u003cstrong\u003efirst FDA-cleared all-in-one platform\u003c\/strong\u003e for aesthetic surgery provides a unique market position as of late \u003cstrong\u003e2025\u003c\/strong\u003e. The company also submitted a new \u003cstrong\u003e510(k)\u003c\/strong\u003e for power liposuction label expansion on \u003cstrong\u003eOctober 13, 2025\u003c\/strong\u003e, aiming to further solidify its integrated offering.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eI\u003c\/strong\u003emitability: Medium. The first-mover advantage is significant, but competitors will attempt to replicate the integrated feature set. The established workflow and proprietary Renuvion technology within the platform present barriers to rapid imitation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eO\u003c\/strong\u003erganization: High. The company is actively executing a \u003cstrong\u003enationwide commercial launch\u003c\/strong\u003e initiated in \u003cstrong\u003eSeptember 2025\u003c\/strong\u003e. This organizational execution is reflected in the upward revision of financial guidance following the launch.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. The advantage is tied to the initial integrated offering and first-mover status, which will be challenged as competitors develop competing platforms.\u003c\/p\u003e\n\n\u003cp\u003eThe impact of the AYON launch on the \u003cstrong\u003eThird Quarter 2025\u003c\/strong\u003e results (ended \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e) is evident in the following figures:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Amount\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncreased by \u003cstrong\u003e12.1%\u003c\/strong\u003e (from $11.5 million in Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical Aesthetics Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncreased by \u003cstrong\u003e19%\u003c\/strong\u003e or \u003cstrong\u003e$1.8 million\u003c\/strong\u003e (from $9.3 million in Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e64.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from \u003cstrong\u003e60.5%\u003c\/strong\u003e in Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Attributable to Stockholders\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecreased by \u003cstrong\u003e58.6%\u003c\/strong\u003e (from $4.7 million in Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecreased by \u003cstrong\u003e96%\u003c\/strong\u003e (from $2.4 million in Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe momentum from the AYON launch led to an upward revision of the full-year \u003cstrong\u003e2025 revenue guidance\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY2025 Total Revenue Guidance Range: \u003cstrong\u003e$50.5 million to $52.5 million\u003c\/strong\u003e, an increase from the previous range of \u003cstrong\u003e$50.0 million to $52.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY2025 Surgical Aesthetics Revenue Guidance Range: \u003cstrong\u003e$43 million to $45 million\u003c\/strong\u003e, up from the previous range of \u003cstrong\u003e$42 million to $44 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company's market capitalization was reported at \u003cstrong\u003e$167 million\u003c\/strong\u003e as of \u003cstrong\u003eDecember 3, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eApyx Medical Corporation (APYX) - VRIO Analysis: Extensive Clinical Evidence Base (Over 90 Clinical Documents)\n\u003c\/h2\u003e\n\u003cp\u003eThe core technology's effectiveness is supported by more than \u003cstrong\u003e90\u003c\/strong\u003e clinical documents.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides crucial credibility and validation for surgeons and hospital systems, reducing perceived risk for adoption of new procedures.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium. Many med-tech firms have studies, but over \u003cstrong\u003e90\u003c\/strong\u003e documents supporting the core technology is a significant, defensible moat.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Medium. Competitors can fund their own studies, but they cannot instantly replicate Apyx Medical Corporation's decade-plus body of published work.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management consistently highlights this evidence base in investor communications, showing it's central to their strategy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Clinical data is a long-term asset that builds trust over time.\u003c\/p\u003e\n\n\u003cp\u003eThe clinical evidence base underpins the Advanced Energy segment, which reported total revenue of \u003cstrong\u003e$12.1 million\u003c\/strong\u003e in the fourth quarter of 2024.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Q4 2024)\u003c\/th\u003e\n\u003cth\u003eValue (Full Year 2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$48.10 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Attributable to Stockholders\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$23.46 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Change Y\/Y\u003c\/td\u003e\n\u003ctd\u003eDecreased by \u003cstrong\u003e52%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eIncreased by \u003cstrong\u003e25.4%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe established clinical foundation supports market expansion, such as the South Korea cosmetic surgery market, estimated at \u003cstrong\u003e$1.7 billion\u003c\/strong\u003e in 2024.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eThe body of work includes peer-reviewed articles published in journals such as \u003cem\u003eAesthetic Plastic Surgery\u003c\/em\u003e and \u003cem\u003eAesthetic Surgery Journal Open Forum\u003c\/em\u003e, reviewing Renuvion results.\u003c\/li\u003e\n\u003cli\u003eThe Company continues to plan for the launch of the AYON Body Contouring System™ in the second half of 2025, pending U.S. FDA clearance.\u003c\/li\u003e\n\u003cli\u003eThe Renuvion and J-Plasma effectiveness is supported by the more than \u003cstrong\u003e90\u003c\/strong\u003e clinical documents.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eApyx Medical Corporation (APYX) - VRIO Analysis: Strong Q3 2025 Commercial Momentum and Guidance\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Demonstrates successful execution post-AYON launch, translating to tangible financial results, like the Q3 2025 revenue of $12.9 million and raised FY2025 guidance to $50.5 million to $52.5 million.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe commercial momentum is quantified by key financial metrics from the third quarter ended September 30, 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Value\u003c\/td\u003e\n\u003ctd\u003ePrior Year Q3 Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$11.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical Aesthetics Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$9.3 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEM Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecrease of 18% from prior year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e64.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e60.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Attributable to Stockholders\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$4.7 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$2.4 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe upward revision of the full-year 2025 revenue guidance reflects this performance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY2025 Total Revenue Guidance Raised to \u003cstrong\u003e$50.5 million to $52.5 million\u003c\/strong\u003e from previous guidance of $50.0 million to $52.0 million.\u003c\/li\u003e\n\u003cli\u003eSurgical Aesthetics Segment Revenue Guidance Raised to \u003cstrong\u003e$43.0 million to $45.0 million\u003c\/strong\u003e from previous guidance of $42.0 million to $44.0 million.\u003c\/li\u003e\n\u003cli\u003eThe new guidance compares to the original FY2025 guidance range of $47.6 million to $49.5 million.\u003c\/li\u003e\n\u003cli\u003eU.S. Surgical Aesthetics revenue increased \u003cstrong\u003eover 30%\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eDomestic revenue for Q3 2025 was \u003cstrong\u003e$9.3 million\u003c\/strong\u003e, a \u003cstrong\u003e20%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Low. Strong sales are the goal for every company, but the rate of guidance increases is notable.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhile strong sales are expected, the immediate impact following the full U.S. commercial launch of AYON in September 2025 is noteworthy:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company initiated the full U.S. commercial launch of AYON at the end of Q3 2025.\u003c\/li\u003e\n\u003cli\u003eDemand for pre-orders for AYON exceeded expectations.\u003c\/li\u003e\n\u003cli\u003eThe company narrowed its net loss by \u003cstrong\u003e58.6%\u003c\/strong\u003e year-over-year in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Low. This is a performance metric, not a static resource, though the underlying driver (AYON demand) is valuable.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe current financial performance is a result of a recent event, the AYON launch, which is not inherently inimitable in the long term, but the initial market reception is a current advantage.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: High. The sales team is clearly organized to capitalize on the new product launch.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOrganizational alignment is evidenced by resource allocation shifts and financial outcomes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eManagement affirmed a strategic shift, redirecting resources from OEM towards the Surgical Aesthetics segment, particularly the AYON launch.\u003c\/li\u003e\n\u003cli\u003eOEM revenue guidance was revised downward to approximately \u003cstrong\u003e$7.5 million\u003c\/strong\u003e from $8 million as resources were focused on Surgical Aesthetics.\u003c\/li\u003e\n\u003cli\u003eCash used in operating activities for the quarter was \u003cstrong\u003e$3.5 million\u003c\/strong\u003e, a substantial year-over-year reduction.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of September 30, 2025, were \u003cstrong\u003e$25.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary. This momentum is tied to the initial AYON launch cycle; it must be sustained by follow-on products.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is tied to the initial market penetration of a new product, which competitors will attempt to replicate.\u003c\/p\u003e\n\u003cp\u003eThe company submitted a new 510(k) for AYON for device label expansion to include power liposuction.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eApyx Medical Corporation (APYX) - VRIO Analysis: International Market Penetration and Expansion\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Diversifies revenue away from the U.S. and taps into high-growth aesthetic markets, evidenced by Renuvion sales in China and the Q4 2025 planned shipments to South Korea. The company has made significant progress in bringing Renuvion to China, the third largest market for aesthetic surgery. Initial commercial orders for the Apyx One console in South Korea are expected in Q4 2025, with shipments planned to start in the fourth quarter of 2025. The cosmetic surgery market in South Korea is estimated to be \u003cstrong\u003e$1.7 billion in 2024\u003c\/strong\u003e and projected to exceed \u003cstrong\u003e$3.9 billion by 2033\u003c\/strong\u003e. International revenue for the full year ended December 31, 2024, was approximately \u003cstrong\u003e$14.0 million\u003c\/strong\u003e. For the three months ended September 30, 2024, international revenue was \u003cstrong\u003e$3.7 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe following table details relevant international financial and market data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Period\u003c\/th\u003e\n\u003cth\u003eSource Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Revenue (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-over-year increase of 11% in Q3 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Revenue (FY 2024)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$14.0 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eEssentially flat year-over-year compared to FY 2023.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSouth Korea Cosmetic Surgery Market (2024 Est.)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarket size prior to planned Q4 2025 shipments.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSouth Korea Cosmetic Surgery Market (2033 Proj.)\u003c\/td\u003e\n\u003ctd\u003eExceed \u003cstrong\u003e$3.9 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eProjected market size.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina Market Position\u003c\/td\u003e\n\u003ctd\u003eThird largest market for aesthetic surgery\u003c\/td\u003e\n\u003ctd\u003eMarket targeted for Renuvion sales.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium. Having established regulatory pathways and distribution in key international markets like China and South Korea is not common for smaller players.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Medium. Regulatory hurdles and establishing local distribution partners take significant time and capital. The company's progress in China followed initial regulatory clearance.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company is actively pursuing international growth as a key pillar of its strategy. The company plans to expand internationally, targeting Europe, the Middle East, and Brazil.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Regulatory approvals and established foreign partnerships create high switching costs for competitors.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company has secured regulatory approval by the Ministry of Food and Drug Safety (MFDS) in South Korea.\u003c\/li\u003e\n\u003cli\u003eProgress in China involved initial regulatory clearance and the activation of a distribution partner, GlamMoon Medical Technology.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eApyx Medical Corporation (APYX) - VRIO Analysis: OEM Revenue Stream from Unique Waveform Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOEM Revenue Stream from Unique Waveform Expertise\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\nValue: Provides a non-core, relatively stable revenue floor, leveraging the company's deep engineering knowledge in unique energy delivery without direct sales\/marketing costs.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEM Revenue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEM Revenue (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEM Revenue YoY Change (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-18%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2025 OEM Revenue Guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~$7.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2024 OEM Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~$9.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nRarity: Medium. Leveraging specific waveform expertise for OEM deals is a niche capability in the broader device space.\n\u003c\/p\u003e\n\u003cp\u003e\nImitability: High. It requires specific, proven engineering talent and established trust with other large device manufacturers.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe OEM segment is subject to customer-specific agreements, such as the \u003cstrong\u003e10-year\u003c\/strong\u003e generator manufacturing and supply agreement with \u003cstrong\u003eSymmetry Surgical\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe strategic focus has shifted, with Surgical Aesthetics revenue reaching \u003cstrong\u003e$11.1 million\u003c\/strong\u003e in Q3 2025, compared to OEM revenue of \u003cstrong\u003e$1.8 million\u003c\/strong\u003e in the same period.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\nOrganization: Medium. While the revenue exists, the company seems more focused on its direct Surgical Aesthetics segment now.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eManagement has explicitly shifted manufacturing resources from OEM towards the Surgical Aesthetics segment, particularly the \u003cstrong\u003eAYON\u003c\/strong\u003e launch.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Gross Margin was \u003cstrong\u003e64.4%\u003c\/strong\u003e, compared to \u003cstrong\u003e60.5%\u003c\/strong\u003e in Q3 2024, reflecting the higher-margin focus.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\nCompetitive Advantage: Temporary. OEM agreements can be lost if a partner develops internal capabilities or switches suppliers.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Attributable to Stockholders\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(2.0) million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(0.1) million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (as of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eApyx Medical Corporation (APYX) - VRIO Analysis: Active Regulatory Pipeline (Power Liposuction 510(k) Submission)\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue: Positions AYON to become the definitive, single-platform solution by adding a critical function (power liposuction), which could significantly expand its addressable market.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe AYON system, upon clearance, is positioned as the first fully integrated body contouring platform. The addressable market expansion is linked to the estimated over 15 million patients using GLP-1 drugs who may require body contouring. The initial AYON submission targeted the $15.9 billion global body contouring market. The company's Q3 2025 Surgical Aesthetics revenue reached $11.1 million, increasing over 30% in the U.S..\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eAYON integrates multiple modalities: fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities.\u003c\/li\u003e\n\u003cli\u003eThe power liposuction feature uses a reciprocating liposuction cannula to facilitate fat removal with reduced manual effort for surgeons.\u003c\/li\u003e\n\u003cli\u003eThe system includes Renuvion for tissue contraction, which is the only FDA-cleared device for use after liposuction.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePre-Power Liposuction Clearance (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003ePost-Power Liposuction Clearance (Projected)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAYON Integration Status\u003c\/td\u003e\n\u003ctd\u003ePartial (Excluding Power Liposuction)\u003c\/td\u003e\n\u003ctd\u003eFully Integrated Platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 Total Revenue Guidance\u003c\/td\u003e\n\u003ctd\u003eRange of $50.5 million to $52.5 million\u003c\/td\u003e\n\u003ctd\u003ePotential for upward revision beyond $52.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical Aesthetics Revenue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e$11.1 million\u003c\/td\u003e\n\u003ctd\u003eExpected to increase with expanded indication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e$25.1 million\u003c\/td\u003e\n\u003ctd\u003eExpected to support activation in installed systems\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: Low. Submitting 510(k)s is standard, but the breadth of the planned expansion is strategic.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe initial AYON 510(k) submission was completed 90 days ahead of schedule. The company reported a 210% stock surge in the six months prior to the October 2025 submission.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: Medium. Competitors can submit their own, but Apyx Medical Corporation has the first-mover advantage on the integrated system.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe company submitted the power liposuction 510(k) in October 2025. The initial AYON system received 510(k) clearance in May 2025. The company anticipates the power liposuction label expansion could be activated in AYON systems already installed across the U.S. upon clearance.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: High. Management is proactively seeking label expansion immediately following the initial launch.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe full U.S. commercial launch of AYON was initiated in September 2025. The company reported an Adjusted EBITDA loss decrease of 96% to $0.1 million in Q3 2025, compared to $2.4 million in Q3 2024. The company's current ratio was 4.72.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Temporary. Once cleared, the advantage shifts to the product's performance, not just the submission status.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe company's Q3 2025 total revenue was $12.9 million. The company's FY2025 revenue guidance was increased to a range of $50.5 million to $52.5 million.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eApyx Medical Corporation (APYX) - VRIO Analysis: Alignment with Post-GLP-1 Market Tailwinds\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue: The growing patient population seeking solutions for loose skin after significant weight loss creates a massive, secular demand driver for body contouring technologies like Renuvion and AYON.\u003c\/h\u003e\n\u003cp\u003eRenuvion is the only FDA approved device for the revolutionary treatment of loose and lax skin post liposuction and contracting subcutaneous soft tissue anywhere on the body. The company aims to capitalize on the growing demand from over 15 million GLP-1 drug users seeking body contouring solutions. Management believes Renuvion is well-positioned to become the standard-of-care for the rapidly growing patient population on GLP-1 drugs who choose to address their loose skin post-weight loss.\u003c\/p\u003e\n\u003cp\u003eThe potential U.S. market opportunity is quantified as follows:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Metric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Estimated U.S. Surgeons (Plastic, Cosmetic, Derm)\u003c\/td\u003e\n\u003ctd\u003e~\u003cstrong\u003e15,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Annual U.S. Surgical Body Contouring Procedures\u003c\/td\u003e\n\u003ctd\u003e~\u003cstrong\u003e700,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Annual U.S. Liposuction Procedures\u003c\/td\u003e\n\u003ctd\u003e~\u003cstrong\u003e384,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated U.S. Market Opportunity (Annual)\u003c\/td\u003e\n\u003ctd\u003e+\u003cstrong\u003e$1B+\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue FY 2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$52.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: Low. This is an external market factor, but Apyx Medical Corporation is perfectly positioned to capture it.\u003c\/h\u003e\n\u003cp\u003eThe macro trend of GLP-1 adoption is an external factor, not controlled by Apyx Medical Corporation. However, Renuvion’s status as the only FDA-cleared device for use after liposuction provides a unique, current product advantage within this emerging demand wave. The AYON Body Contouring System received FDA 510(k) clearance in May 2025.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: Low. No company can imitate the macro trend of GLP-1 adoption.\u003c\/h\u003e\n\u003cp\u003eThe secular growth driver is an external, non-imitable market shift. Apyx Medical Corporation’s proprietary balance of Helium Plasma and RF energy in Renuvion is a key differentiator. The AYON system integrates multiple technologies including fat removal, closed loop contouring, and tissue contraction via Renuvion technology. The company is planning an expansion of AYON capabilities with an additional 510(k) submission for power liposuction later in 2025.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: High. Management explicitly calls out this opportunity in investor calls.\u003c\/h\u003e\n\u003cp\u003eManagement commentary confirms strategic focus on this area:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eManagement stated they see more opportunities due to the rapid uptake in GLP-1 drugs and associated loose skin side effects.\u003c\/li\u003e\n\u003cli\u003eThe company reaffirmed its FY2025 Total Revenue guidance to a range of \u003cstrong\u003e$50.5 million to $52.5 million\u003c\/strong\u003e as of November 2025.\u003c\/li\u003e\n\u003cli\u003eThe company reported a 96% reduction in Adjusted EBITDA loss for Q3 2025 to \u003cstrong\u003e$0.1 million\u003c\/strong\u003e, compared with \u003cstrong\u003e$2.4 million\u003c\/strong\u003e for Q3 2024.\u003c\/li\u003e\n\u003cli\u003eThe full U.S. commercial launch of AYON was initiated at the end of Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Sustained. This macro trend is expected to persist for several years.\u003c\/h\u003e\n\u003cp\u003eThe anticipated long-term adoption curve of GLP-1 weight loss medications suggests a sustained demand for body contouring procedures over several years. The company’s FY2025 Surgical Aesthetics revenue projection is \u003cstrong\u003e$43.0 million to $45.0 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eApyx Medical Corporation (APYX) - VRIO Analysis: Improved Operational Efficiency and Loss Reduction\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Shows management's ability to control costs and scale effectively, evidenced by the Adjusted EBITDA loss shrinking to just \u003cstrong\u003e$0.1 million\u003c\/strong\u003e in Q3 2025, a \u003cstrong\u003e96%\u003c\/strong\u003e year-over-year improvement.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Adjusted EBITDA loss for Q3 2025 was \u003cstrong\u003e$0.1 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$2.4 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Net loss attributable to stockholders for Q3 2025 was \u003cstrong\u003e$2.0 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$4.7 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Operating expenses for Q3 2025 decreased to \u003cstrong\u003e$9.1 million\u003c\/strong\u003e, from \u003cstrong\u003e$10.6 million\u003c\/strong\u003e in the prior year period.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium. Achieving near break-even status after a major launch is a sign of strong financial discipline.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Cost control and operational restructuring are internal processes that are difficult for outsiders to replicate.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The restructuring completed last year is clearly paying dividends now.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. A culture of cost-consciousness, once embedded, is a long-term advantage, especially for a growth-stage company.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e 13-week cash flow forecast incorporation of raised FY2025 revenue guidance (as of Friday, November 6, 2025, reporting date).\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eLatest Reported Value (Q3 2025 or As of 9\/30\/2025)\u003c\/th\u003e\n\u003cth\u003ePrior Period\/Guidance Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaised FY2025 Total Revenue Guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50.5 million to $52.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from previous range of $50.0 million to $52.0 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 Surgical Aesthetics Revenue Guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43.0 million to $45.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from previous guidance of $42.0 million to $44.0 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 OEM Revenue Guidance\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$7.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDown from previous guidance of $8.0 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (As of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to $31.7 million as of December 31, 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Used in Operating Activities (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecreased from $4.4 million in the prior year period.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Used in Operating Activities (9 Months Ended 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecreased from $15.1 million in the prior year period.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company believes, based on cash projections, working capital management, and strict cost controls, it will yield cash through \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal revenue for Q3 2025 was \u003cstrong\u003e$12.9 million\u003c\/strong\u003e, a \u003cstrong\u003e12%\u003c\/strong\u003e increase year-over-year.\u003c\/li\u003e\n\u003cli\u003eGross profit margin for Q3 2025 increased to \u003cstrong\u003e64.4%\u003c\/strong\u003e compared to \u003cstrong\u003e60.5%\u003c\/strong\u003e in the prior year period.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516113805461,"sku":"apyx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/apyx-vrio-analysis.png?v=1740147383","url":"https:\/\/dcf-model.com\/products\/apyx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}